Protecting future antimalarials from the trap of resistance:Lessons from artemisinin-based combination therapy (ACT) failures  

作　　者：Nekpen Erhunse Dinkar Sahal 

机构地区：[1]Malaria Drug Discovery Research Group,International Centre for Genetic Engineering and Biotechnology,New Delhi,110067,India [2]Department of Biochemistry,Faculty of Life Sciences,University of Benin,Benin City,Edo-State,Nigeria

出　　处：《Journal of Pharmaceutical Analysis》2021年第5期541-554,共14页药物分析学报（英文版）

摘　　要：Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine(DHA-PPQ),Cambodia swapped the first line artemisinin-based combination therapy(ACT)from DHA-PPQ to artesunate-mefloquine given that parasites resistant to piperaquine are susceptible to mefloquine.However,triple mutants have now emerged,suggesting that drug rotations may not be adequate to keep resistance at bay.There is,therefore,an urgent need for alternative treatment strategies to tackle resistance and prevent its spread.A proper understanding of all contributors to artemisinin resistance may help us identify novel strategies to keep artemisinins effective until new drugs become available for their replacement.This review highlights the role of the key players in artemisinin resistance,the current strategies to deal with it and suggests ways of protecting future antimalarial drugs from bowing to resistance as their predecessors did.

关 键 词：Artemisinin resistance QUIESCENCE K13 mutations Non-K13 mutations Artemisinin-based combination therapy (ACT)failure Drugs in development Malaria eradication 

分 类 号：R978.61[医药卫生—药品]